Progress in adjuvant systemic therapy for breast cancer

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Breast cancer patient prognosis has significantly improved over 30 years.
• Adjuvant endocrine therapy and chemotherapy have driven progress, but often involve therapeutic escalation with associated costs and toxicities.
• Identifying patient subgroups benefiting from escalated treatment remains challenging due to limited collaboration and slow drug development.

Purpose of the Study:

• To review historical approaches to escalating and de-escalating adjuvant systemic treatment for breast cancer.
• To advocate for innovative clinical trial designs prioritizing patient needs over market size.
• To emphasize the necessity of international collaboration for adopting effective, harm-reducing treatments.

Main Methods:

• Review of published literature on adjuvant systemic treatment trials in early-stage breast cancer.
• Analysis of trends in therapeutic escalation and de-escalation strategies.
• Discussion of challenges in clinical trial design and drug development.

Main Results:

• Therapeutic escalation in early-stage breast cancer has improved outcomes but increased costs and toxicities.
• De-escalation initiatives have shown success in recent decades.
• Identifying patient subgroups for targeted therapy remains a significant hurdle.

Conclusions:

• Future breast cancer treatment strategies require creative trial designs focused on genuine patient needs.
• International collaboration among researchers, governments, and industry is essential for implementing effective and safe treatments.
• A shift towards de-escalation, guided by patient benefit and reduced harm, is necessary for sustainable progress in breast cancer care.